  | April 2025 |   | ||||
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | |||
Special issue article publications often bring higher citations and visibility than regular papers and attract more relevant readership due to its scope. Topoi is indexed in the Web of Science under AHCI, currently in Quartile 1 and placed in the top-10 ranked Philosophy-Category journals, with a 2023 IF of 1,3 and CiteScore of 3,1.
Guest Editors:
· Stefania Achella, Full Professor of History of Philosophy at University of Chieti-Pescara, Email: stefania.achella@unich.it
· Jean-Gabriel Ganascia, University Pierre et Marie Curie of Paris, Email: Jean-Gabriel.Ganascia@lip6.fr
Evidence-Based Medicine Reconsidered
April 5, 2025 @ 8:00 am - April 6, 2025 @ 5:00 pm EDT
Senior Visiting Fellow Conference by Carl Hoefer
The evidence-based medicine (EBM) movement began in the 1980s, reached its peak perhaps in the 1990s, and has since then enjoyed the status of orthodoxy, despite many criticisms being raised among medical practitioners and researchers. Philosophers of medicine have frequently criticized EBM’s hierarchies and rigid precepts, especially the “gold standard” status of randomized controlled trials (RCTs). A pluralistic approach to evidence in medicine has been increasingly popular in recent years, in which mechanistic evidence and reasoning, observational studies of many kinds and RCTs are assessed for value on a case-by-case basis. But does this trend away from the EBM hierarchy go too far and risk the reintroduction of the same biased, motivated evidence-gathering practices that originally motivated the EBM movement? What light can recent experiences in medicine and public health (e.g., during the covid-19 pandemic) shed on these issues?
Evidence-Based Medicine Reconsidered
Conference Dates: April 5-6th, 2025
10th Floor Cathedral of Learning
Senior Visiting Fellow Conference by Carl HoeferThe evidence-based medicine (EBM) movement began in the 1980s, reached its peak perhaps in the 1990s, and has since then enjoyed the status of orthodoxy, despite many criticisms being raised among medical practitioners and researchers. Philosophers of medicine have frequently criticized EBM’s hierarchies and rigid precepts, especially the “gold standard” status of randomized controlled trials (RCTs). A pluralistic approach to evidence in medicine has been increasingly popular in recent years, in which mechanistic evidence and reasoning, observational studies of many kinds and RCTs are assessed for value on a case-by-case basis. But does this trend away from the EBM hierarchy go too far and risk the reintroduction of the same biased, motivated evidence-gathering practices that originally motivated the EBM movement? What light can recent experiences in medicine and public health (e.g., during the covid-19 pandemic) shed on these issues?